Most clinicians training in psychedelic-assisted therapy focus first on protocol: dosing windows, screening criteria, the mechanics of preparation and integration sessions. Self-compassion, when it comes up at all, tends to get filed under “supportive stance” — something therapists already do, applied in a slightly unusual setting. A recent first-person account published in the Journal of Transpersonal Research, and summarized for a general audience on Psychology Today, argues that this framing understates what’s actually happening. For providers building or refining a PAT practice, the distinction matters more than it first appears.
What the Case Report Actually Claims
Psychologist Sebastian Salicru describes his own experience in a medically supervised MDMA-assisted group therapy session, in which a memory he’d considered fully resolved after three decades of clinical practice and intermittent personal therapy resurfaced with what he describes as unexpected clarity. His account frames the mechanism specifically: MDMA’s known effects on trust, emotional openness, and reduced fear response created room for an unusually direct encounter with self-criticism, and self-compassion — not just relaxation or euphoria — was the operative ingredient in what followed.
This tracks with the broader theoretical model self-compassion researchers have built over the past two decades: a triad of self-kindness versus self-judgment, common humanity versus isolation, and mindful awareness versus over-identification with one’s own suffering. The clinical argument in the psychedelic literature is that MDMA — and, differently, psilocybin — can temporarily loosen the second half of each pair (judgment, isolation, over-identification), giving patients direct access to the first half (kindness, connection, mindful distance) in a way that talk therapy alone often can’t reach quickly, particularly with patients whose self-criticism is deeply entrenched.
For providers, the practical takeaway isn’t that this validates psychedelics generically. It’s a more specific claim: if self-compassion access is a load-bearing mechanism rather than an incidental mood effect, then how a therapist actively works with self-compassion during and after a session — rather than simply holding space and waiting for insight to arrive — becomes a trainable, assessable clinical skill, not just a personality trait some therapists happen to have.
The Therapist’s-Own-Experience Question, and Why It Won’t Go Away
The article leans into a more contentious argument that’s been circulating in the PAT training literature: that therapists should have their own firsthand experience with altered states of consciousness to competently guide patients through them. The reasoning is that a therapist without that reference point risks misjudging what “set and setting” actually requires, developing expectations that don’t match the patient’s experience, or missing cues during a session that someone with direct experience would recognize.
This is not a settled question, and providers should treat it as one still under real debate rather than emerging consensus. The counterarguments are substantial: requiring personal psychedelic experience as a training prerequisite creates obvious problems around legality in many jurisdictions, equity of access to training (personal retreats and legal clinical trials are expensive and geographically limited), and the risk of conflating a therapist’s own psychedelic experience with actual competence in facilitating someone else’s. A therapist’s single MDMA session tells them a great deal about their own psychology and very little, directly, about how to handle a patient’s markedly different reaction — dissociation, panic, or a psychotic-spectrum response, for instance, none of which the therapist’s own comfortable experience necessarily prepares them to manage.
The more defensible middle position, and the one most training programs currently building certification tracks seem to be converging on, is that experiential components — supervised, legal, and appropriately bounded — belong in training curricula as one input among several, not as a licensing requirement, and that programs need to be explicit about what a therapist’s personal experience does and doesn’t transfer to clinical skill.
Where This Sits in the Actual Regulatory Picture
It’s worth being precise here, since the pace of policy activity in this space has outstripped what’s actually approved. As of mid-2026, MDMA-assisted therapy is not FDA-approved for any indication in the United States. The FDA issued a Complete Response Letter to the MDMA-AT application in August 2024, citing gaps in the safety and efficacy data, and MDMA remains investigational and federally Schedule I outside of registered clinical trials — including newer trials backed by the Department of Defense and the VA for military-connected PTSD populations.
The regulatory momentum in 2026 has actually shifted toward psilocybin rather than MDMA. Following an April 2026 executive order directing federal agencies to accelerate review of psychedelic treatments for serious mental illness, the FDA issued National Priority Vouchers — compressing standard review timelines from 10–12 months down to one to two months — to three companies: Compass Pathways and the Usona Institute, both developing psilocybin for depression indications, and Transcend Therapeutics, developing an MDMA-like compound called methylone for PTSD. Notably, Lykos Therapeutics (now Resilient Pharmaceuticals), the company behind the original MDMA-AT application, did not receive one of the three vouchers. Compass Pathways is targeting a rolling New Drug Application submission in the final quarter of 2026, with a possible approval decision by late 2026 or early 2027. Psilocybin itself remains federally Schedule I regardless of this accelerated review track.
Separately, and more relevant to therapists practicing today, a handful of states have built their own regulated frameworks independent of federal approval — Oregon and Colorado both operate licensed psilocybin service programs, with Colorado’s expanding to other plant-based psychedelics under a longer implementation timeline. These state programs, not the federal drug-approval pipeline, are where most legally practicing PAT facilitators in the U.S. currently operate, and their training and supervision requirements vary meaningfully by state.
The practical implication for providers: the “regulated medical framework” that PAT is reportedly transitioning into is real but partial and uneven — a patchwork of state licensing programs and clinical trials rather than an approved, insurance-reimbursable standard of care. Providers building competence in this area now are training for a landscape that’s still being drawn, and treatment models validated in one state’s psilocybin program won’t automatically transfer to whatever federal framework eventually emerges for a differently regulated substance.
What This Means for Building Clinical Competence Now
For therapists and psychiatrists actively moving into this space, a few practical threads follow from the self-compassion argument specifically, independent of the broader firsthand-experience debate:
- Self-compassion work deserves explicit protocol attention, not just general supportive presence. Therapists preparing patients for PAT sessions can build self-compassion skills — accepting rather than judging one’s own painful material — directly into preparation sessions, rather than treating it as something the medicine will simply produce on its own.
- Integration is where the mechanism either holds or doesn’t. A session that surfaces self-compassion in the moment doesn’t automatically anchor it afterward; sustained change likely depends on how integration sessions reinforce and generalize that state, especially for patients with deeply practiced self-criticism.
- Track training requirements against the jurisdiction, not the headlines. With most legal PAT practice currently happening under state programs rather than FDA approval, the actual certification, supervision, and scope-of-practice rules a provider needs to follow are state-specific and changing quickly enough that a program’s requirements from even a year ago may already be outdated.
- Treat the personal-experience question as a training design choice, not a competence guarantee. Programs that include supervised experiential components should be explicit with trainees about what those components are meant to build — self-awareness and reference points — versus what they don’t automatically confer, which is clinical judgment for managing a patient’s different and possibly adverse reaction.
The self-compassion argument is a useful corrective to a training culture that’s still mostly organized around dosing and safety protocol. It suggests that some of the most consequential clinical work in PAT — helping a patient move from self-judgment to self-acceptance during a narrow window of reduced defensiveness — is exactly the kind of skill that can be taught, practiced, and supervised, rather than left to whatever the substance happens to produce.
Sources:
- Salicru, S. (2026). “A healing experience with MDMA: A psychotherapist’s mini-autoethnographic case study.” Journal of Transpersonal Research, 18(1), 29–40.
- Psychology Today, “The Power of Self-Compassion in Psychedelic-Assisted Therapy,” July 12, 2026
- Negrine, J.J. et al. (2026). “You can only take your clients as far as you’ve been yourself”: examining the intersections between psychedelic-assisted therapy, lived-living experience, and clinical practice. Drugs: Education, Prevention and Policy
- Villiger, D. (2024). Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited? International Review of Psychiatry, 36(8), 869–878
- Nielson, E.M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies, 2(2), 64–73
- Neff, K. (2023). Self-compassion: Theory, method, research, and intervention. Annual Review of Psychology
- MAPS (Multidisciplinary Association for Psychedelic Studies), public statements on MDMA-assisted therapy regulatory status, 2024–2026
- Foley & Lardner LLP, “Psychedelics and the Executive Order: From Schedule I to Treatment Priority,” April 2026
- Medical Daily, “The FDA Just Put Psilocybin and an MDMA-Like Drug on a 1-to-2 Month Approval Track,” June 2026
Discover more from Doctor Trusted
Subscribe to get the latest posts sent to your email.
